Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 21Etoposide 20Carboplatin 20Topotecan 13pembrolizumab 12durvalumab 11Paclitaxel 10Irinotecan 9Nivolumab 7Gemcitabine 7tremelimumab 6atezolizumab 6Radiotherapy 6Docetaxel 6Pemetrexed 5Ipilimumab 5Cyclophosphamide 5rovalpituzumab tesirine 4budigalimab 4Specimen Handling 4Injections 4Doxorubicin 4Bortezomib 4130-nm albumin-bound paclitaxel 4venetoclax 3talazoparib 3olaparib 3fludarabine 3etoposide phosphate 3Platinum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Small Cell Lung Carcinoma × OSI 930 × Clear all
NCT00513851 2011-09-27

Phase 1 Study of OSI-930 in Cancer Patients

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡